Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up safety study of Temferon in glioblastoma multiforme
2021-000700-38Phase 2Active
- Sponsor
- Genenta Science
- Start
- Jun 2021
- Modality
- Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Temferon in glioblastoma (GBM), sponsored by Genenta Science. Primary endpoint: Incidence of hematopoietic malignancies and other malignancies over 8 years. Started Jun 2021; status: active.
02
Drugs
Temferon
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2021-000700-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000700-38.